Scinus Cell Expansion is pleased to announce that as of 1 January 2025, Dr. Erik Vossenaar has taken up the role of Managing Director of the company.   Prior to joining Scinus, Erik Vossenaar was Senior Vice President of Corporate Business Development and Strategy at Biocartis, an innovative molecular diagnostics…

During BIO-Europe in Stockholm, Scinus Cell Expansion marked a significant step forward in establishing a collaborative relationship with Region Skåne by signing a Letter of Intent with the ATMP-Center at Skåne University Hospital. Together, our aim is to drive innovation and progress in the field of cell and gene therapy.…

In our previous blogpost, we shed a light on all the different possibilities that HEK293T cells have to offer. Now, in this second edition of our \'Ask the Expert\' series, we will interview our PhD student Javier Olmos Becerra. He’s been working on optimizing HEK293T expansion in the SCINUS bioreactor…

HEK293T cells, derived from human embryonic kidney cells, are widely used in gene therapy research due to their transfection efficiency and capability to produce different types of viral vectors. These cells are especially suitable for generating lentiviral (LV) vectors, which makes them a valuable tool for CAR T cell therapy…

Scinus Cell Expansion is attending the Bioprocessing Summit in Boston! From 19th till 22nd of August, Scinus Cell Expansion will be attending the 16th annual Bioprocessing Summit in Boston! We’re excited to discuss today’s challenges and advances in bioprocess R&D and scale-up, as well as the future of bioprocessing. Also,…

Organoids have emerged as a revolutionary tool in drug discovery and clinical practice. These miniature 3D structures, cultivated from stem cells or differentiated cells, mimic the architecture and function of organs, offering a significant advancement over traditional cell culture methods. Organoids have demonstrated remarkable potential in disease modeling, drug screening,…

Scinus Cell Expansion is moving to Zeist As of June 1st, Scinus Cell Expansion will be located at the Utrecht Science Park location in Zeist! This place provides a vibrant, dynamic and exciting place to work, where industry and academia come together. Feel free to stop by whenever you are…

To standardize iPSC differentiation and production to a level necessary for producing therapy grade cells, Process Development Engineer Juda-El Sam from Scinus Cell Expansion is working on developing protocols for iPSC expansion using the SCINUS bioreactor NG. “At the time they were developed, iPSCs presented the first real alternative to…

The unique nature of induced pluripotent stem cells (iPSCs) lies in their capability for unlimited self–renewal and programmed differentiation into virtually any adult cell types [1]. iPSC based technology holds the potential to treat a multitude of diseases and conditions, ranging from neurodegenerative disorders like Parkinson\'s and Alzheimer\'s disease to…

SCINUS simplifies operational procedures and significantly diminishes the overall cost of ownership.